319 related articles for article (PubMed ID: 28274788)
1. Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.
Biegstraaten M; Cox TM; Belmatoug N; Berger MG; Collin-Histed T; Vom Dahl S; Di Rocco M; Fraga C; Giona F; Giraldo P; Hasanhodzic M; Hughes DA; Iversen PO; Kiewiet AI; Lukina E; Machaczka M; Marinakis T; Mengel E; Pastores GM; Plöckinger U; Rosenbaum H; Serratrice C; Symeonidis A; Szer J; Timmerman J; Tylki-Szymańska A; Weisz Hubshman M; Zafeiriou DI; Zimran A; Hollak CEM
Blood Cells Mol Dis; 2018 Feb; 68():203-208. PubMed ID: 28274788
[TBL] [Abstract][Full Text] [Related]
2. Management goals of type 1 Gaucher disease in South Africa: An expert Delphi consensus document on good clinical practice.
Louw VJ; Fraser I; Giraldo P
PLoS One; 2023; 18(8):e0290401. PubMed ID: 37607165
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic goals in the treatment of Gaucher disease.
Pastores GM; Weinreb NJ; Aerts H; Andria G; Cox TM; Giralt M; Grabowski GA; Mistry PK; Tylki-Szymańska A
Semin Hematol; 2004 Oct; 41(4 Suppl 5):4-14. PubMed ID: 15468045
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease.
Hughes D; Cappellini MD; Berger M; Van Droogenbroeck J; de Fost M; Janic D; Marinakis T; Rosenbaum H; Villarubia J; Zhukovskaya E; Hollak C
Br J Haematol; 2007 Sep; 138(6):676-86. PubMed ID: 17655728
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and Management of Gaucher Disease in India - Consensus Guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics.
Puri RD; Kapoor S; Kishnani PS; Dalal A; Gupta N; Muranjan M; Phadke SR; Sachdeva A; Verma IC; Mistry PK;
Indian Pediatr; 2018 Feb; 55(2):143-153. PubMed ID: 29503270
[TBL] [Abstract][Full Text] [Related]
6. Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status.
Giraldo P; Pérez-López J; Núñez R; de la Puebla RF; Luño E; Saura-Grau S; Bureo JC; Plaza S; de la Serna J
Blood Cells Mol Dis; 2016 Jan; 56(1):23-30. PubMed ID: 26603719
[TBL] [Abstract][Full Text] [Related]
7. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus.
Kishnani PS; Al-Hertani W; Balwani M; Göker-Alpan Ö; Lau HA; Wasserstein M; Weinreb NJ; Grabowski G
Mol Genet Metab; 2022 Feb; 135(2):154-162. PubMed ID: 34972655
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Khan A; Hangartner T; Weinreb NJ; Taylor JS; Mistry PK
J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
[TBL] [Abstract][Full Text] [Related]
9. Gaucher disease: an overview of clinical characteristics and therapy.
Kingma W
J Intraven Nurs; 1996; 19(2):79-82. PubMed ID: 8852167
[TBL] [Abstract][Full Text] [Related]
10. A neurological symptom survey of patients with type I Gaucher disease.
Pastores GM; Barnett NL; Bathan P; Kolodny EH
J Inherit Metab Dis; 2003; 26(7):641-5. PubMed ID: 14707512
[TBL] [Abstract][Full Text] [Related]
11. The impact of Gaucher disease and its treatment on quality of life.
Hayes RP; Grinzaid KA; Duffey EB; Elsas LJ
Qual Life Res; 1998 Aug; 7(6):521-34. PubMed ID: 9737142
[TBL] [Abstract][Full Text] [Related]
12. Goal-oriented therapy with miglustat in Gaucher disease.
Pastores GM; Giraldo P; Chérin P; Mehta A
Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
[TBL] [Abstract][Full Text] [Related]
13. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.
Grabowski GA; Andria G; Baldellou A; Campbell PE; Charrow J; Cohen IJ; Harris CM; Kaplan P; Mengel E; Pocovi M; Vellodi A
Eur J Pediatr; 2004 Feb; 163(2):58-66. PubMed ID: 14677061
[TBL] [Abstract][Full Text] [Related]
14. [Gaucher disease in Latin America. A report from the Gaucher Disease International Registry and the Latin American Group for Gaucher Disease].
Drelichman G; Linares A; Villalobos J; Cabello JF; Kerstenetzky M; Kohan RM; Martins AM
Medicina (B Aires); 2012; 72(4):273-82. PubMed ID: 22892077
[TBL] [Abstract][Full Text] [Related]
15. [Gaucher disease: A review].
Nguyen Y; Stirnemann J; Belmatoug N
Rev Med Interne; 2019 May; 40(5):313-322. PubMed ID: 30638965
[TBL] [Abstract][Full Text] [Related]
16. Management of neuronopathic Gaucher disease: a European consensus.
Vellodi A; Bembi B; de Villemeur TB; Collin-Histed T; Erikson A; Mengel E; Rolfs A; Tylki-Szymanska A;
J Inherit Metab Dis; 2001 Jun; 24(3):319-27. PubMed ID: 11486896
[No Abstract] [Full Text] [Related]
17. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy.
Deegan PB; Pavlova E; Tindall J; Stein PE; Bearcroft P; Mehta A; Hughes D; Wraith JE; Cox TM
Medicine (Baltimore); 2011 Jan; 90(1):52-60. PubMed ID: 21200186
[TBL] [Abstract][Full Text] [Related]
18. South African guidelines for the management of Gaucher disease, 2011.
; Bhengu L; Davidson A; du Toit P; Gerntholtz T; Govendragaloo K; Heitner R; Henderson B; Mubaiwa L; Varughese S
S Afr Med J; 2012 Jun; 102(8):697-702. PubMed ID: 22831951
[TBL] [Abstract][Full Text] [Related]
19. Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease.
Dinur T; Istaiti M; Frydman D; Becker-Cohen M; Szer J; Zimran A; Revel-Vilk S
Orphanet J Rare Dis; 2020 Oct; 15(1):284. PubMed ID: 33050940
[TBL] [Abstract][Full Text] [Related]
20. Individualization of long-term enzyme replacement therapy for Gaucher disease.
Andersson HC; Charrow J; Kaplan P; Mistry P; Pastores GM; Prakash-Cheng A; Rosenbloom BE; Scott CR; Wappner RS; Weinreb NJ;
Genet Med; 2005 Feb; 7(2):105-10. PubMed ID: 15714077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
